These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6224472)

  • 1. Moxalactam penetration of normal and osteomyelitic bone.
    Fitzgerald RH
    Arch Orthop Trauma Surg (1978); 1983; 101(4):273-81. PubMed ID: 6224472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of moxalactam in serum, bone, tissue fluid, and peritoneal fluid.
    Wittmann DH; Schassan HH
    Rev Infect Dis; 1982; 4 Suppl():S610-6. PubMed ID: 6218573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of cefazolin into normal and osteomyelitic canine cortical bone.
    Daly RC; Fitzgerald RH; Washington JA
    Antimicrob Agents Chemother; 1982 Sep; 22(3):461-9. PubMed ID: 7137985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic distribution in normal and osteomyelitic bone.
    Fitzgerald RH
    Orthop Clin North Am; 1984 Jul; 15(3):537-46. PubMed ID: 6472833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects.
    Peterson LR; Bean B; Fasching CE; Korchik WP; Gerding DN
    Antimicrob Agents Chemother; 1981 Sep; 20(3):378-81. PubMed ID: 6458235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.
    Wise R; Baker S; Livingston R
    Antimicrob Agents Chemother; 1980 Sep; 18(3):369-71. PubMed ID: 6252833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of moxalactam in patients with normal and impaired renal function.
    Aronoff GR; Sloan RS; Luft FC
    J Infect Dis; 1982 Mar; 145(3):365-9. PubMed ID: 6460824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.
    Kaplan SL; Mason EO; Garcia H; Kvernland SJ; Loiselle EM; Anderson DC; Mintz AA; Feigin RD
    J Pediatr; 1981 Jan; 98(1):152-7. PubMed ID: 6450278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetration of moxalactam and cefazolin into bone following simultaneous bolus or infusion.
    Polk R; Hume A; Kline BJ; Cardea J
    Clin Orthop Relat Res; 1983; (177):216-21. PubMed ID: 6222858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and clinical evaluation of moxalactam in infants and children.
    Latif R; Thirumoorthi MC; Buckley JA; Kobos DM; Aravind MK; Kauffman RE; Dajani AS
    Dev Pharmacol Ther; 1981; 3(4):222-31. PubMed ID: 6212231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The penetration of moxalactam into bone (author's transl)].
    Wittmann DH; Schassan HH; Kohler F; Seidel H
    Unfallchirurgie; 1981; 7(3):142-6. PubMed ID: 6455002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal and fetal pharmacokinetics of moxalactam given intrapartum.
    Bawdon RE; Cunningham FG; Quirk JG; Roark ML
    Am J Obstet Gynecol; 1982 Nov; 144(5):546-50. PubMed ID: 6215864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxalactam epimer kinetics in children.
    Nahata MC; Durrell DE; Barson WJ
    Clin Pharmacol Ther; 1982 Apr; 31(4):528-32. PubMed ID: 6460588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography.
    Diven WF; Obermeyer BD; Wolen RL; Yu VL; Lyon J; Zuravleff J
    Ther Drug Monit; 1981; 3(3):291-5. PubMed ID: 6459665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state moxalactam kinetics: comparisons with other cephalosporins.
    Garzone P; Lyon J; Yu VL; Zuravleff J; Diven W; Pasculle W
    Clin Pharmacol Ther; 1981 Jul; 30(1):86-94. PubMed ID: 6453677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of LY127935, a broad spectrum oxa-beta-lactam.
    Wise R; Baker S; Wright N; Livingston R
    J Antimicrob Chemother; 1980 May; 6(3):319-22. PubMed ID: 6447137
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of probenecid on the pharmacokinetics of moxalactam.
    DeSante KA; Israel KS; Brier GL; Wolny JD; Hatcher BL
    Antimicrob Agents Chemother; 1982 Jan; 21(1):58-61. PubMed ID: 6211135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxalactam--absorption, excretion, distribution, and metabolism.
    Shimada J; Ueda Y
    Rev Infect Dis; 1982; 4 Suppl():S569-80. PubMed ID: 6218568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of Moxalactam (6059-S): the chemistry and biology of 1-oxacephems.
    Otsuka H; Nagata W; Yoshioka M; Narisada M; Yoshida T; Harada Y; Yamada H
    Med Res Rev; 1981; 1(3):217-48. PubMed ID: 6213825
    [No Abstract]   [Full Text] [Related]  

  • 20. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.
    Polk RE; Kline BJ; Markowitz SM
    Antimicrob Agents Chemother; 1981 Nov; 20(5):576-9. PubMed ID: 6459759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.